Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
posted on 2020-03-10, 11:13authored byLisa H. Lancaster, Claudia Valenzuela, Wendi Mason, Claus Neurohr, Elena Ripamonti, Klaus-Uwe Kirchgaessler, Vincent Cottin
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).